Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis

Table 4

Composition of peritoneal leukocytes.

Treatment	Five weeks				Seven weeks
Group	I	II	III	IV	I	II	III	IV
Cell number ×10^6	22.1	19.5	99.8	153.9	24.95	22.9	122.75	92.25
IQR	12.5–24.8]	16.2–24.2]	89.0–130.1]	108.1–186.1]	20.3–26.7]	17.3–26.3]	109.4–144.9]	46.9–153.4]
Macrophages (%)	77.0	80.0	84.7	78.9	89	88.5	88	86.5
IQR	74.0–81.0]	76.6–82.1]	72.3–90.4]	68.8–87.7]	85.8–90.3]	87.5–90.3]	85.8–92.5]	79.5–91.8]
Lymphocytes (%)	0.0	0.0	0.5	0.4	0	0	1	3
IQR	0.0–0.0]	0.0–0.0]	0.3–1.3]	0.0–0.9]	0–1.25]	0–0.3]	0.5–1.8]	0.8–4.5]
Neutrophils (%)	0.0	0.0	7.25	14.1	0.5	0	4	2
IQR	0.0–0.0]	0.0–0.0]	2.5–25.8]	10.6–20.2]	0–1]	0–0]	0–8.8]	0–9]
Eosinophils (%)	11.3	13.8	2.3	1.75	10.5	11	3	5.5
IQR	9.0–13.9]	11.3–14.6]	1.5–5.4]	0.6–11.9]	9.8–11.3]	9.8–11.8]	[1.8–5.3]	2–6.5]
Mast cells (%)	9.8	7.3	0.0	0.0	0	0	0	0
IQR	8.8–13.6]	4.5–10.4]	0.0–0.3]	0.0–0.2]	0–0]	0–0]	0–0]	0–0]

All data presented as median and interquartiles.
compared to C group; compared to C group; compared to C group.